Rosario García-Campelo
A5055885018- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Dietary Effects on Health
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Advanced Biosensing Techniques and Applications
- Global Cancer Incidence and Screening
- Ferroptosis and cancer prognosis
- Clinical practice guidelines implementation
- Economic and Financial Impacts of Cancer
- Immune Cell Function and Interaction
- Health, Environment, Cognitive Aging
Complexo Hospitalario Universitario A Coruña
2021-2025
Universidade da Coruña
2025
Servicio Gallego de Salud
2025
Instituto de Investigación Biomédica de A Coruña
2023-2024
Abstract Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for NSCLC, using major (MPR) as primary endpoint. Eighty-three received a single cycle of treatment: 26 durvalumab (anti–PD-L1) monotherapy, 21 plus oleclumab (anti-CD73), 20...
Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food Drug Administration (FDA) approval of nivolumab plus resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage tumors do not completely respond therapy, which been associated early disease progression. So far, it is impossible predict these events due...
Abstract Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of cancers. Only one-third patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum–etoposide adjuvant therapy, although only minority with SCLC qualify for surgery. Concurrent chemo-radiotherapy the standard care LS-SCLC that not surgically resectable, prophylactic cranial irradiation (PCI) without progression. For...
Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.
Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath's and Hannum's clocks, perform poorly predicting chronological tissue, underscoring the need for a tissue-specific approach. In this study, we introduce Breast Tissue-specific Clock (BTEC), developed using DNA methylation data from 553 healthy samples seven different studies. BTEC significantly outperformed...
<title>Abstract</title> Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly predicting chronological tissue, underscoring the need for a tissue-specific approach. In this study, we introduce Breast Tissue-specific Clock (BTEC), developed using DNA methylation data from 553 healthy samples seven different studies. BTEC...
Perioperative chemoimmunotherapy (ChIO) has become a paradigm shift in the treatment of patients with locally advanced non-small cell lung cancer (NSCLC), considerably increasing complete pathological response (CPR) and survival rates. The role played by B lymphocytes antitumor emerges as crucial factor fight against cancer, although mechanisms remain to be elucidated. Therefore, main objective this study is identification lymphocyte-related biomarkers perioperative NSCLC. For purpose, tumor...
Objective Liquid biopsy (LB) is a non-invasive technique to detect genetic alterations by next-generation sequencing (NGS) when tissue not available. This study aims estimate in the Spanish setting, cost-effectiveness of using FoundationOne CDx (F1L CDx), novel blood-derived LB test based on NGS, versus non-molecular diagnosis (non-mDx) patients with advanced non-small cell lung cancer (NSCLC) whom sampling feasible.
Background Evaluation of quality care in oncology is key ensuring patients receive adequate treatment. American Society Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI) Certification Program (QCP) an international initiative that evaluates outpatient practices. Methods We retrospectively reviewed free-text electronic medical records from with breast cancer (BR), colorectal (CRC) or non-small cell lung (NSCLC). In a baseline measurement, high scores were obtained for the...
<p>Supplementary Figures</p>
<p>Supplementary File</p>
<p>Supplementary File</p>
<div>AbstractPurpose:<p>Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.</p>Experimental Design:<p>We analyzed tumor samples from 58 patients with ES-SCLC enrolled two multicenter single-arm phase IIIb studies evaluating frontline Spain:...
<div>AbstractPurpose:<p>Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.</p>Experimental Design:<p>We analyzed tumor samples from 58 patients with ES-SCLC enrolled two multicenter single-arm phase IIIb studies evaluating frontline Spain:...
<p>Supplementary Figures</p>
Pembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such antibiotic exposure, low body mass index (BMI), certain metastatic location or poor performance status may influence outcomes.
<div>Abstract<p>Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for NSCLC, using major (MPR) as primary endpoint. Eighty-three received a single cycle of treatment: 26 durvalumab (anti–PD-L1) monotherapy, 21 plus oleclumab...
<p>Additional details on safety endpoints. Supplementary tables: 1, Representativeness of study participants; 2, Efficacy summary; 3, Adverse events occurring in ≥10% patients; 4, Treatment-related adverse ≥5% 5, special or potential interest; 6, Baseline biomarker association with response. figures: Mechanism action for each drug; Violin plots median % residual viable tumor cells; Additional immunohistochemistry to major pathological response; Calculation gene signatures associated...
<p>Additional details on safety endpoints. Supplementary tables: 1, Representativeness of study participants; 2, Efficacy summary; 3, Adverse events occurring in ≥10% patients; 4, Treatment-related adverse ≥5% 5, special or potential interest; 6, Baseline biomarker association with response. figures: Mechanism action for each drug; Violin plots median % residual viable tumor cells; Additional immunohistochemistry to major pathological response; Calculation gene signatures associated...